Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
81-100 of 1,738 trials

Serious Bacterial Infections in Children: Aztreonam-Avibactam Study

We are investigating a new treatment for serious gram-negative bacterial infections in children aged 9 months to under 18 years. The study compares this treatment to the best available therapy to assess safety and effectiveness.

Hospital-Acquired PneumoniaVentilator-Associated PneumoniaComplicated Gram-Negative Bacterial Infections≤3 monthsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPediatrics

Long-Term Safety of Miltenyi CAR T Cell Therapy

We are studying the long-term effects of Miltenyi CAR T cell therapy on patients, especially children. This includes monitoring safety, disease progression, and overall survival.

Unresectable Stage III or IV MelanomaRelapsed or Refractory B Cell Non-Hodgkin's LymphomaRelapsed or Refractory CD20 Positive B-Cell Non-Hodgkin’s Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyHematologyOncology

Itacitinib: Continued Treatment Study

We are providing ongoing treatment for participants who have benefited from itacitinib in earlier studies. This study aims to evaluate the safety of continued use of this medication.

Chronic Graft Versus Host DiseaseBronchiolitis Obliterans SyndromeMyelofibrosisEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInternal MedicineOncology

Continued Treatment with Parsaclisib for Blood Disorders

We are providing ongoing treatment for patients who have previously participated in studies of parsaclisib. The goal is to evaluate the safety of this medication alone or with other therapies.

Advanced CancerAutoimmune Hemolytic AnemiaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Neuroblastoma: Comparing PET-CT and SPECT-CT Scans

We are studying whether a new PET-CT scan can better detect lesions in patients with neuroblastoma compared to a standard SPECT-CT scan. This may help improve diagnosis and treatment options for patients.

Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

COVID-19 Treatment: LTX-109 Nasal Spray Study

We are testing a new nasal spray for people with COVID-19 or similar symptoms to see if it helps them recover faster and clear the virus. The study will also monitor safety and overall wellbeing during treatment.

Respiratory Tract InfectionCOVID-19COVID-like Illness≤3 monthsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Mantle Cell Lymphoma: Venetoclax with Ibrutinib and Rituximab

We are studying a new treatment combination for patients with Mantle Cell Lymphoma who cannot undergo high-dose therapy. The goal is to see how well it works compared to standard chemotherapy.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Myeloma: [68Ga]Ga-PentixaFor PET Imaging Study

We are studying a new imaging method to see how accurately it detects myeloma at the beginning of treatment. This may help improve risk assessment and disease management for patients.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Glioblastoma: L19TNF and Lomustine Study

We are evaluating a new treatment combining L19TNF with lomustine for patients with glioblastoma at their first progression. This study aims to understand how safe and effective this combination is.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Psilocybin for Hospitalized Patients with Treatment-Resistant Depression

We are studying the safety and feasibility of psilocybin-assisted psychotherapy for patients with treatment-resistant depression in a hospital setting. This research aims to explore its effects on depression and the overall experience of patients.

Treatment-Resistant DepressionEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesPartially RemotePsychiatry

Leukemia and Lymphoma: Dasatinib and Venetoclax Study for Children

We are testing two new drugs for children with relapsed or refractory leukemia or lymphoma that have specific genetic mutations. The goal is to assess safety and see if these drugs can effectively treat their condition.

Lymphoblastic Lymphoma and Acute Lymphoblastic Leukemia1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Leukemia and Lymphoma: Ruxolitinib and Venetoclax Study

We are studying the safety and effectiveness of ruxolitinib and venetoclax in children with relapsed or refractory leukemia or lymphoma that have specific genetic mutations. This research aims to find better treatment options for these young patients.

Lymphoblastic Lymphoma and Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Hematological Cancers in Children: New Drug Combination Study

We are testing a combination of Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for children with relapsed or refractory hematological malignancies. The goal is to assess safety and see if it works for patients with specific genetic changes.

Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Acute Ischemic Stroke: Redasemtide Study

We are investigating whether redasemtide can improve recovery in adults who have had an acute ischemic stroke. Participants will receive either the medication or a placebo to compare effects.

Ischaemic Stroke>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNeurology

Rituximab for Heart Attack Recovery

We are studying whether a single injection of rituximab can improve heart function in patients who have had a heart attack. This trial compares its effects to a placebo to see if it helps reduce heart damage.

ST Segment Elevation Myocardial InfarctionAcute Myocardial Infarction>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Prostate Cancer: Apalutamide with Radiation Therapy

We are studying whether adding stereotactic body radiation therapy to Apalutamide improves treatment outcomes for men with low burden metastatic hormone-sensitive prostate cancer. This trial compares standard treatment alone to the combination therapy.

Prostate Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Ovarian Cancer: REGN5668 with Cemiplimab or REGN4018

We are studying the safety and effectiveness of REGN5668 when given with either Cemiplimab or REGN4018 for patients with ovarian cancer. This trial aims to find the best dose and see how well these combinations work.

Fallopian Tube CancerPrimary Peritoneal CancerOvarian CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Ovarian Cancer: Niraparib and Abemaciclib Combination

We are studying the effects of combining niraparib and abemaciclib for patients with late-stage ovarian cancer. This trial aims to see if this treatment can improve outcomes for those who have already received other therapies.

Ovarian Cancer>2 yearsSafety phase (I)Efficacy phase (II)Gynecology and ObstetricsOncology

Inclusion Body Myositis: ABC008 Treatment Study

We are studying the safety and effectiveness of a new treatment called ABC008 for people with Inclusion Body Myositis. The goal is to see if it improves muscle function and strength compared to a placebo.

Inclusion Body Myositis1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyRheumatology

Abdominal Aortic Aneurysm: Stem Cell Treatment Study

We are testing whether injecting stem cells into the aneurysm sac is safe and effective for patients undergoing endovascular repair. This study compares outcomes with those from traditional treatment methods.

Abdominal Aortic Aneurysm1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCardiologyInternal MedicineOrthopedics and Traumatology